';
CLOSE
Children's Services

0 441

Tuesday, January 6, 2026
1:00 pm – 2:00 pm ET; 12:00 pm – 1:00 pm CT;
11:00 am – 12:00 pm MT; 10:00 am – 11:00 am PT
Register Here

Please join us as the IPRC hosts special guest Terry Carolan from CARF International, who will share the new Disorders of Consciousness Program Standards.

Presenter Bio:

Terrence Carolan
Terrence Carolan, Managing Director of the Medical Rehabilitation and Aging Services accreditation areas at the Commission on Accreditation of Rehabilitation Facilities (CARF), has more than 20 years of experience as a provider, administrator, and educator in the human services field. Terry joined CARF after working in clinical and administrative leadership positions within Select Medical’s Inpatient Rehabilitation Division and the Kessler Institute for Rehabilitation since 2001. Terry was a CARF surveyor for 10 years and holds a degree in physical therapy from Simmons College in Boston. He also recently completed his master’s degree in business administration from the University of Wisconsin-Eau Claire.

Objectives: At the end of this session, the learner will:

  • Describe recent research and guidance on the treatment of individuals with Disorders of Consciousness (DoC);
  • Discuss how CARF International has responded to guidance from the field to create Disorders of Consciousness Program Standards; and
  • Analyze how new DoC accreditation and recent research will enhance access to rehabilitation for children with DoC in the future.

Audience: This webinar is intended for all interested members of the rehabilitation team; attendees do not need to be CARF certified in order to attend.

Level: Beginner-Intermediate

Certificate of Attendance: Certificates of attendance are available for all attendees. No CEs are available for this course.

0 768

Message from the Office of Mental Health and Substance Abuse Services (OMHSAS):

The Pennsylvania Department of Human Services’ (DHS) Office of Mental Health and Substance Abuse Services (OMHSAS) is issuing the bulletin OMHSAS-25-05 “Behavioral Health Clinic Services Provided Outside of the Clinic,” effective November 12, 2025, following changes to Federal Regulation 42 CFR 440.90(d).

OMHSAS 25-05 announces an amendment to Pennsylvania’s Medicaid State Plan which allows all behavioral health clinics that are enrolled in the Medical Assistance (MA) Program, who deliver services through the fee-for-service and managed care systems, to provide clinically appropriate services outside of the clinic. Behavioral health clinics include psychiatric outpatient clinics, outpatient drug and alcohol clinics, and methadone maintenance clinics.

Furthermore, OMHSAS-25-05 also announces the abrogation of 55 Pa Code §§ 1153.14(6) (relating to noncovered services) and 55 Pa. Code 1223.14(11) (relating to noncovered services) by Act 46 of 2025.

The guidance in OMHSAS-25-05 is separate from any “telehealth only” licensure and guidance that may be in place. The changes discussed in this bulletin also do not apply to the existing Mobile Mental Health Telehealth (MMHT) services.

Questions and comments can be directed to OMHSAS via email. RCPA members can also contact RCPA COO and MH Policy Director Jim Sharp with any questions.

0 222

RCPA is excited to host a membership benefits webinar on Wednesday, January 14, 2026, at 1:00 pm, as an opportunity for members to orient themselves with all that RCPA membership includes. This is not just for new and future members. For current members, there may be benefits associated with our membership that you may not be aware of, including targeted meetings and groups that are held throughout the year.

Registration is required; please register here to attend the webinar. Attendees will have the opportunity to:

  • Virtually meet the dedicated RCPA Policy Staff and RCPA lobbyists;
  • Discuss the 2026 Legislative and Administrative priorities;
  • Preview RCPA divisional committee and subcommittee meetings and what they offer;
  • View the RCPA member-only website;
  • Review exclusive yearly educational and networking events; and
  • Understand the value of the National Council and ANCOR memberships included with RCPA membership.

Visit the RCPA member benefits web page for more information, or contact Tieanna Lloyd for benefit details.

0 1433

On November 13, 2025, President Trump signed the executive order “Fostering the Future for American Children and Families,” an initiative to be led by the Office of the First Lady. The order is aimed at supporting children transitioning out of foster care into adulthood by modernizing the out-of-date child welfare system.

The Secretary of Health and Human Services must take the appropriate actions for the following within the next 180 days:

  • Update regulations, policies, and practices to improve data collection;
  • Promote modernization of child welfare information systems;
  • Expand States’ use of technological solutions; and
  • Publish an annual scorecard to measure and evaluate State-level achievement.

The HHS Secretary, in coordination with the First Lady and heads of other applicable offices, are to establish a “Fostering the Future” initiative to develop partnerships with agencies, private sector organizations, academic institutions, and non-profit entities to aid in the transition out of the foster care system. The order also calls for the development of an online platform to assist in the navigation of the transition, and an increase in the role of Education and Training Vouchers and educational scholarships. This initiative will be funded by the reallocation of funds returned by the States from Federal programs designed to assist in the transition out of foster care, but further details have not been clarified.

The final section of the Executive Order outlines the role of HHS in coordination with the Director of the White House Office of Faith and the White House Office of Intergovernmental Affairs, to:

“(a) take appropriate action to address State and local policies and practices that inappropriately prohibit participation in federally-funded child-welfare programs by qualified individuals or organizations based upon their sincerely held religious beliefs or moral convictions; and (b) take appropriate actions to increase partnerships between agencies and faith-based organizations and houses of worship to serve families whose children have been placed in foster care or are at risk of being placed in foster care.”

This order explicitly encourages partnerships with faith-based organizations and removes barriers for faith-motivated foster/adoptive families. While faith-based groups currently play a significant role in the foster care system, this order increases ethical tensions regarding what safeguards exist to protect foster youth who come from non-religious or different religious/cultural backgrounds from pressure to conform.

Further concerns with this order lay with language regarding “biological truths.” This term implies that LGBTQIA+, non-binary, or gender non-conforming individuals somehow conflict with science and is used to delegitimize trans and nonbinary identities. There is concern that partnerships with faith-based and other community organizations may not align with youth’s identities, especially older youth in the LGBTQIA+ community. Further guidance will be needed to ensure that any partnerships with faith-based organizations must be voluntary and respectful of each youth’s identity.

Additional concerns arise regarding equity of family selection and pairing/matching systems. Preferential selection of faith-based foster/adoptive families may lead to “religious filtering.” Potential foster/adoptive parents may be selected not on their capacity to care or their qualifications, but on religious affiliation or ideological alignment — which could lead to unfair exclusion of qualified non-religious or differently religious households. Upcoming policy changes could undermine equity and non-discrimination in the foster care system.

RCPA will keep abreast of developments on this issue and further guidance for agencies and individuals involved in the foster care system.

Please contact Emma Sharp with any questions.

0 2310

The Office of Developmental Programs (ODP) has shared this important announcement from the U. S. Food and Drug Administration (FDA).

The FDA is aware that Abbott Diabetes Care has sent all affected customers, distributors, and health care providers a letter regarding an issue with certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors providing incorrect low glucose readings. If undetected, incorrect low glucose readings over an extended period may lead to wrong treatment decisions for people living with diabetes, such as excessive carbohydrate intake or skipping or delaying insulin doses. These decisions may pose serious health risks, including potential injury or death, or other less serious complications.

As of November 14, 2025, Abbott has reported 736 serious injuries and seven deaths associated with this issue.

Affected Product

  • FreeStyle Libre 3 Sensor
    • Model Numbers: 72081-01, 72080-01
    • Unique Device Identifiers (UDI-DI): 00357599818005, 00357599819002
  • FreeStyle Libre 3 Plus Sensor
    • Model Numbers: 78768-01, 78769-01
    • Unique Device Identifiers (UDI-DI): 00357599844011, 00357599843014
  • Download the full list of affected lots

What to Do:

Patients should verify if their sensors are impacted and immediately discontinue use and dispose of the affected sensor(s).

On November 24, 2025, Abbott Diabetes Care sent all affected customers a letter recommending the following actions:

  • For Patients:
    • Determine if your current or unused sensor(s) are affected by visiting FreeStyle Check and selecting “CONFIRM SENSOR SERIAL NUMBER.” You will need to locate your sensor serial number to determine if your sensor is affected.
      • If you are wearing a FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensor, you can find the serial number in the app or reader. The serial number can also be found on the label on the bottom of the sensor applicator or carton. (If you are using a sensor with a connected insulin delivery device, please refer to the connected insulin delivery device user manual on how to locate the sensor serial number.)
    • If you are currently wearing or have a FreeStyle Libre 3 or FreeStyle Libre 3 Plus sensor that has been confirmed as potentially affected on FreeStyle Check or by a customer service representative, immediately discontinue use and dispose of the affected sensor(s).
    • You can request a replacement for any potentially affected sensor(s) on FreeStyle Check. Select “CONFIRM SENSOR SERIAL NUMBER” and enter a valid serial number. If your sensor is potentially impacted, you will be instructed to enter your contact information so a replacement product can be sent to you at no cost.
    • Use a blood glucose meter or the built-in meter in your FreeStyle Libre 3 Reader to make treatment decisions when your sensor readings don’t match your symptoms or expectations.

Visit the FDA’s website for additional information and instructions on how to locate the Sensor’s Serial Number.

0 6187

Message from the Center for Connected Health Policy (CCHP):

On November 10, 2025, the U.S. Drug Enforcement Administration (DEA) posted a fourth temporary extension of the COVID-19 telemedicine flexibilities for prescribing controlled substances. These flexibilities were set to expire at the end of the year. Although the DEA has not yet released the full text of the extension — including how long it will last. At this point, the final rule is still pending regulatory review. Historically, extensions have added a year of continued flexibility, though this extension could be shorter. For context, the previous extension, issued in November 2024, extended the telemedicine allowances through December 31, 2025. Until the fourth extension rule is approved and the complete text published, the duration and any potential policy adjustments remain unknown.

As background, permanent federal law under the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 largely prohibits the prescribing of controlled substances without an initial in-person examination. While the statute outlines several exceptions under the defined “practice of telemedicine,” these apply primarily when a patient is located in a hospital or clinic or in the presence of another practitioner. As a result, these exceptions do not cover the routine model of telehealth widely used today, in which the patient (and sometimes the provider) participate from home settings. Importantly, the in-person requirement under the Ryan Haight Act applies only to the initial visit, and the DEA has never required subsequent in-person encounters. While the full details are not yet available, it is likely that the forthcoming temporary extension will mirror previous ones by continuing to suspend the initial in-person visit requirement for the period of the extension.

It is important to note that these DEA extensions affect only federally-controlled substance prescribing rules. States maintain their own requirements, which may include stricter requirements for in-person visits prior to the prescribing of controlled substances. Please check the Online Prescribing category of CCHP’s Policy Finder to reference state specific requirements.

Additionally, the DEA’s in-person prescribing requirement is separate from Medicare’s policy requiring an in-person visit within six months prior to an initial telehealth mental health service and annually thereafter. That Medicare mental health requirement — often confused with the DEA’s prescribing standard — is tied to Medicare reimbursement rules and applies only to Medicare beneficiaries and providers seeking reimbursement for mental health services through Medicare if their situations do not meet certain exceptions, not to all patients. Additionally, this Medicare in-person visit requirement is currently waived until January 30, 2026 (as passed in the most recent government funding bill), whereas the DEA’s in-person requirement, which is the topic of this particular newsletter and the new fourth extension rule, governs all practitioners prescribing controlled substances nationwide, regardless of payer.

If RCPA members have any questions, please contact RCPA COO and Mental Health Policy Director Jim Sharp.

0 532

Early this year, the FASD Respect Act was introduced in the Senate to authorize and modify programs administered by the Department of Health and Human Services to address fetal alcohol spectrum disorders (FASD), and became a provision of the SUPPORT for Patients and Communities Reauthorization Act. The bill sought to establish FASD Centers for Excellence to support FASD prevention through screenings, public awareness, and trainings at a local and state level. In September, Congress passed the SUPPORT Act, and last week the President signed it into law, which officially authorizes the FASD Respect Act.

The legislation will allow the US Department of Health and Human Services to promote and fund FASD education and awareness, as well as the promotion of FASD resources. Beyond funding and program expansion, the FASD Respect Act will task the federal government with addressing FASD through a realigned perspective that supports individuals and families and respects their lived experience.

Please contact Emma Sharp with any questions.

0 231

The Pennsylvania Department of Human Services’ (DHS) Office of Mental Health and Substance Abuse Services (OMHSAS) and the Office of Medical Assistance Programs (OMAP) have jointly issued the Medical Assistance Bulletin Targeted Case Management Services for Eligible Juveniles Enrolled in Medical Assistance Prior to Release From a Carceral Setting, implementing Section 5121 of the Consolidated Appropriations Act, 2023. Eligible juveniles are individuals under 21 years of age who are determined eligible for MA or an individual 18–25 years of age who was determined eligible for the mandatory eligibility group for former foster care children.

This bulletin advises providers of billing procedures for the physical health (PH) and behavioral health (BH) Targeted Case Management (TCM) services provided to eligible juveniles enrolled in the Medical Assistance (MA) Program within 30 days of release from a carceral setting and for at least 30 days following release. This bulletin also advises providers of a new provider specialty (Spec) for TCM services.

Questions and comments can be sent electronically. You can also contact RCPA Policy Associate Emma Sharp with any questions.

123...143Next Page 1 of 143
© 2021 - Rehabilitation & Community Providers Association